Drug Approval | January 09, 2026
BeOne Medicines wins first-in-world nod for Sonrotoclax in China
The approval is backed by data showing deep, durable responses and manageable tolerability
The approval is backed by data showing deep, durable responses and manageable tolerability
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Subscribe To Our Newsletter & Stay Updated
